700 patients to reveal how new arthritis drugs perform in the real world

NCT ID NCT07166315

Recruiting now Knowledge-focused Sponsor: Adelphi Real World Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will follow 700 adults with axial spondyloarthritis or psoriatic arthritis who have recently started one of several newer treatments (bimekizumab, upadacitinib, risankizumab, guselkumab, or a TNF inhibitor). Researchers will collect medical records and patient surveys to see how well these treatments control disease activity and improve quality of life over 12 months. The goal is to understand real-world effectiveness from both doctor and patient perspectives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study succeeds, it could help doctors understand which treatments work best for these conditions in everyday practice.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or incomplete data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLARTHRITIS (AXSPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis psoriatic arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AXIAL SPONDYLARTHRITIS (AXSPA) PSORIATIC ARTHRITIS (PSA)

Contacts and locations

Locations

Royal National Hospital for Rheumatic Diseases
RECRUITING

Bath, Somerset, BA1 3NG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.